Royalty Report: Drugs, Cancer, Disease – Collection: 203265

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Diagnostic
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 203265

License Grant
For the research license, Licensor grants to Licensee and its Affiliates, a non-exclusive, worldwide, without the right to sublicense, under the Licensors Technology solely to perform Licensee’s obligations under the Research Plan.

For the Development and Commercialization License, Licensor grants an exclusive, worldwide license, with the right to sublicense, under the Licensor Technology and interest in the Joint Patents, to develop, make, have made, use, sell, distribute for sale, offer for sale, have sold and import or export Products in the Field.

License Property
Licensor is engaged in the research, development and commercialization of pharmaceutical products.

The licensed technology includes MX128495 is a lead compound in the MX90745 series of apoptosis induction compounds and preclinical research suggests that it is active in several anticancer animal models.  The MX90745 Series shall mean the series of compounds described in U.S. provisional patent application 60/493,006.

MX90745 is  a new family of apoptosis inducing molecules with potent in vivo anti-cancer activities.

Field of Use
The Field shall mean the treatment and/or prevention of any disease or disorder.  Licensee is engaged in the research, development and commercialization of pharmaceutical products.

IPSCIO Record ID: 289543

License Grant
The Parties are collaborating in the discovery, development and commercialization of products for use in the prevention, and/or treatment of certain human diseases as identified below.

Licensor grants under the Licensor Patents,  Licensor Know How and Licensors interest in the Research Technology and Research Technology Patent Rights:
—  a non-exclusive, worldwide right and license solely to conduct its Research activities pursuant to this Agreement during the Research Term.
—  Commencing at the expiration of the Research Term and for a period of three years thereafter, a non-exclusive, worldwide right and license to optimize and, in connection with Axys activities under this Agreement, make and use, but not sell, offer for sale or import, Candidate Compounds for use in the Field subject to all other provisions of this Agreement relating to Licensed Products.

License Property
Licensor possess proprietary technology and know-how related to modulation of caspases.

Licensor will initially contribute to the Research, from its libraries of compounds, two 2 compounds – each, a Licensor Compound, identified by the Parties which will be the subject of initial research related activities as provided in the Research Plan.

Apoptosis, or programmed cell death, is a necessary and normal function used by the body to remove damaged cells in an orderly way. Apoptosis is mediated by caspases, a cascade of interconnected enzymes inside the cell, which are normally dormant, but become activated under certain stimuli.

Field of Use
The Parties have entered into a collaboration to discover and develop anti-cancer agents that induce apoptosis (programmed cell death).

IPSCIO Record ID: 203285

License Grant
Licensor grants an exclusive, worldwide, non-transferable, license, with the right to sublicense, under the Licensor Patent Rights and Know-How to make, use, including in activities directed at the research and Development of Licensed Compounds, have made, sell, have sold, offer to sell, export, import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.

Licensor grants a non-transferable, non-exclusive license, with the right to sublicense, under the Licensor Other Patent Rights solely to the extent reasonably necessary to make, use (including in activities directed at the research and Development of Licensed Compounds), have made, sell, offer to sell, export and import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.

License Property
MS564929 Toxicology Studies means the two (2) toxicology reports due n the IND covering the BMS compound designated BMS564929, specifically the 6 onth oral toxicology studies in rats and dogs.

6,670,386 – Bicyclic modulators of androgen receptor function

The licensed compounds and patents relate to controlling various diseases and cancers.

Field of Use
The Field means the diagnosis, prevention, treatment or control of any human or animal disease, disorder or condition, excluding the prevention, treatment or control of any human or animal hyperproliferative disease, disorder or condition. For purposes of clarity, hyperproliferative diseases, disorders and conditions are those diseases, disorders or conditions which are characterized by an abnormal increase in the proliferation or accumulation of cells and include conditions such as cancers and benign hyperplasia, but not diseases, disorders or conditions incident to an abnormal increase in the proliferation or accumulation of cells.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.